A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute ...
Wave Life Sciences (NASDAQ:WVE) highlighted upcoming clinical catalysts across its obesity and RNA editing programs during a ...
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR) ...
A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute for Brain Development has ...
Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...
The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomerâ„¢ RNA editing technology platform, today ...
Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...
A research team led by Rice's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1. ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing ...
On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results